SCHEMBL7347286

SCHEMBL7347286

Cc1ccc(S(=O)(=O)N(CC(=O)NO)CC(C)C)cc1

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 9/20 0.76
MMP13 P45452 8/20 0.74
MMP1 P03956 7/20 0.74
MMP8 P22894 7/20 0.74
MMP2 P08253 3/20 0.74
MMP14 P50281 3/20 0.74
MMP9 P14780 2/20 0.74
ADAM17 P78536 1/20 0.74
ADAMTS4 O75173 1/20 0.63
ADAMTS5 Q9UNA0 1/20 0.63
MMP7 P09237 5/20 0.57
MMP12 P39900 5/20 0.57
TAS2R14 Q9NYV8 1/20 0.55
MEP1B Q16820 1/20 0.51
BMP1 P13497 1/20 0.50
THRB P10828 1/20 0.49
MMP16 P51512 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26770100 0.89 MMP3 (0.76) MMP3MMP13MMP1MMP8MMP2
SCHEMBL7340897 0.89 MMP3 (0.76) MMP3MMP13MMP1MMP8MMP2
SCHEMBL7343386 0.87 MMP3 (0.74) MMP3MMP13MMP1MMP8MMP2
SCHEMBL7343903 0.87 MMP3 (0.74) MMP3MMP13MMP1MMP8MMP2
SCHEMBL7349859 0.87 MMP3 (0.74) MMP3MMP13MMP1MMP8MMP2
SCHEMBL7351771 0.87 MMP3 (0.85) MMP3MMP13MMP1MMP8MMP2
SCHEMBL7343818 0.86 MMP3 (1.00) MMP3MMP13MMP1MMP8MMP2
SCHEMBL26770282 0.85 MMP3 (0.70) MMP3MMP13MMP1MMP8MMP2
SCHEMBL598146 0.85 MMP3 (0.79) MMP3MMP13MMP1MMP8MMP2
SCHEMBL7350210 0.84 MMP3 (1.00) MMP3MMP13MMP1MMP8MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0766672-B1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS NOVARTIS AG (CH) 2000-10-04 EP disclosed
EP-0606046-B1 Arylsulfonamido-substituted hydroxamic acids CIBA GEIGY AG (CH) 1997-10-08 EP disclosed
US-5646167-A ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT CIBA-GEIGY CORPORATION (US) 1997-07-08 US disclosed
EP-0766672-A1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS Novartis AG (CH) 1997-04-09 EP disclosed
WO-1996040101-A1 CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS NOVARTIS AG (CH) 1996-12-19 WO disclosed
US-5552419-A METALLOPROTEINASE INHIBITORS CIBA-GEIGY CORPORATION (US) 1996-09-03 US disclosed
US-5506242-A METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA CIBA-GEIGY CORPORATION (US) 1996-04-09 US disclosed
WO-1996000214-A1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS CIBA-GEIGY AG (CH) 1996-01-04 WO disclosed
US-5455258-A Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase CIBA-GEIGY CORPORATION (US) 1995-10-03 US disclosed
EP-0606046-A1 Arylsulfonamido-substituted hydroxamic acids CIBA-GEIGY AG (CH) 1994-07-13 EP disclosed